Theratechnologies Inc. (TH.TO)

1,6600 -0,0400 (-2,35%) Börsenschluss: 03:59PM EDT

Theratechnologies Inc.

2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada
514 336 7800
https://www.theratech.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 103

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Paul Lévesque	President, CEO & Director	1,62M	N/A	1964
Mr. Philippe Dubuc M.B.A., MBA	Senior VP & CFO	593,75k	N/A	1967
Mr. Jocelyn Lafond L.L.M., LL.B.	General Counsel & Corporate Secretary	434,41k	N/A	1968
Dr. Christian Marsolais Ph.D.	Senior VP & Chief Medical Officer	596,9k	N/A	1963
Mr. John Leasure	Global Commercial Officer	578,09k	N/A	1965
Hon. Andre Dupras M.Sc.	Vice President of Human Resources	N/A	N/A	1964

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Corporate Governance

Theratechnologies Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 10, Vorstand: 3, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.